Daclatasvir + Sofosbuvir + Ribavirin in HCV GT-3 Advanced Liver Disease: ALLY-3+ Trial
The ALLY-3+ Trial investigates the efficacy of daclatasvir, sofosbuvir, and ribavirin in patients with chronic HCV GT-3 and advanced liver disease. This Phase 3 study compared 12 versus 16 weeks of treatment in treatment-naive or experienced individuals. Results showed promising SVR12 rates and favo
0 views • 9 slides
Effectiveness of Daclatasvir and Sofosbuvir in HCV Genotype 3: Insights from ALLY-3 Study
Study on the efficacy of Daclatasvir and Sofosbuvir in treating Hepatitis C Virus (HCV) Genotype 3, involving treatment-naive and treatment-experienced patients. The Phase 3 trial showcased promising results in achieving SVR12, with detailed patient characteristics, drug dosing, and baseline charact
0 views • 10 slides
Therapeutic Trials in HIV/HCV Coinfection: ION-4, Ally-2, and Viroteam 2015
In the study of therapeutic trials in HIV/HCV coinfection between 2014-2015, notable trials included ION-4 with LDV/SOF treatment for 12 weeks in HCV/HIV co-infection patients, showing high SVR rates in both treatment-naive and experienced patients. Another trial, Ally-2, involved Daclatasvir and So
0 views • 15 slides